AAV Capsid Variants and Uses Thereof Patent Application
Summary
USPTO published patent application US20260108626A1 for AAV capsid variants on April 23, 2026. The application, originally filed on August 6, 2025, names seven inventors including Mathieu Emmanuel Nonnenmacher, Tyler Christopher Moyer, Jiangyu Li, Dan Richard Laks, Brett Hoffman, Elisabeth Knoll, and Yanqun Shu. The disclosure covers compositions and methods for preparing adeno-associated virus capsid protein variants used in gene therapy and biopharmaceutical applications.
“The disclosure relates to compositions and methods for the preparation, use, and/or formulation of adeno-associated virus capsid protein variants.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108626A1 disclosing novel adeno-associated virus capsid protein variants and their preparation methods. The application covers compositions for use in gene therapy vectors and pharmaceutical formulations. CPC classifications span A61K (pharmaceutical preparations), C07K (peptides), and C12N (microorganisms/vectors), indicating broad biotech and pharma applications. Parties potentially affected include gene therapy developers, pharmaceutical manufacturers, and biotechnology companies engaged in viral vector research. This published application establishes prior art and may impact freedom-to-operate analyses for AAV-based therapy programs.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AAV CAPSID VARIANTS AND USES THEREOF
Application US20260108626A1 Kind: A1 Apr 23, 2026
Inventors
Mathieu Emmanuel Nonnenmacher, Tyler Christopher Moyer, Jiangyu Li, Dan Richard Laks, Brett Hoffman, Elisabeth Knoll, Yanqun Shu
Abstract
The disclosure relates to compositions and methods for the preparation, use, and/or formulation of adeno-associated virus capsid protein variants.
CPC Classifications
A61K 48/0041 A61K 9/0019 A61K 47/64 A61K 48/0058 A61K 48/0075 C07K 7/06 C07K 14/005 C12N 15/86 C12N 2750/14122 C12N 2750/14141 C12N 2750/14143 C12N 2750/14151 C12N 2830/50
Filing Date
2025-08-06
Application No.
19292455
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.